early hepatic complication in first year after bone marrow transplantation in major beta thalassemic patients
نویسندگان
چکیده
background: bone marrow transplantation is a good therapeutic modality for beta thalassemia. liver complications is one of the major causes of morbidity and mortality following bmt. determination of the factors of liver injury leads to earlier diagnosis after bmt and improves prognosis. materials and methods: we studied 113 major beta thalassemic patients who have been transplanted from 1990- 2000 in bone marrow transplantation center of shariati hospital. 62 were male and 51 were female. 27 patients were class one, 56 were class two and 30 were class three. the median age of each classes were 6.5, 6.3 and 8.7 year. conditioning regime consisted of busulfan (3.5-4mg/kg) and cyclophophamide (40-50 mg/kg). for gvhd prophylaxis we gave cyclosporine â± metothrexate. grade of liver fibrosis defined by biopsy in all patients before bmt. all patients and their donors tested for hbsag, hbsab, hcvab, cmvab with ria method. we assessed causes of liver dysfunction before and after transplantation and effect of high ferritin level on liver function. results: hepatic dysfunction in first year after transplantation were seen in 86 (76%) patients. causes of liver dysfunction were consisted of 53.1% gvhd, 15.93% cyclosporine hepatotoxicity, 5.3% conditioning regime hepatotoxicity and 1.77% vod. in all three classes hepatic gvhd, cyclosporine toxicity, death and normal liver function post bmt had significant relation with hepatic dysfunction before bmt (p=0.001). in patients with ferritin level more than 1000, there were significant hepatotoxicity with conditioning regime (p=0.001). 17 (15.04%) of patients have been died.â conclusions: in this study we determined incidence and causes of hepatic dysfunction before and after bmt in major beta thalassemic patients. according to our study the incidence of hepatic dysfunction was 76.1% and hepatic gvhd and drug hepotoxicity were the most common causes of hepatic dysfunction in all three classes. serum ferritin level had not significant relation to gvhd, cyclosporine hepatotoxicity and vod.
منابع مشابه
Bone marrow transplantation in adult thalassemic patients.
One hundred seven adult patients with thalassemia aged from 17 through 35 years and transplanted from HLA-identical siblings between November 1988 and September 1996 were evaluated on December 31, 1997. The outcome experience of 20 consecutive patients transplanted between November 13, 1988 and January 10, 1991 and reported in September 1992 is updated after 5 additional years. The experience o...
متن کاملHepatic failure after bone marrow transplantation.
The article by Beelen et al’ led us to report a case in which the busulfan plus cyclophosphamide preparative regimen for allogeneic bone marrow transplantation terminated in fatal hepatotoxicity. A 31-year-old man with chronic myelogenous leukemia in first chronic phase was bone marrow transplanted from a one DR mismatched donor. Based on encouraging results obtained by Santos et a12 and Tutsch...
متن کاملALLOGENIC BONE MARROW TRANSPLANTATION IN APLASTIC ANEMIA
Eighteen patients, twelve men and six women, with aplastic anemia underwent allogenic bone marrow transplantation (BMT) from HLA-matched siblings during the period of 1990 to 1996. The conditioning regimen was cyclophosphamide with or without busulfan, depending on the cause of aplasia. Antilymphocyte globulin (ALG) and cyclosporine were used for rejection and acute GVHD prophylaxis, respe...
متن کاملBone Marrow Transplantation in Thalassemia (Part 2)
During the last two decades conventional therapy has improved the prognosis of thalassemia. However, despite such improvement it still remains a progressive disease with treatment-related complications such as hepatitis, liver fibrosis, and cardiac disease. Bone marrow transplantation (BMT) can prevent or delay progression of the aforementioned complications. The importance of clinical research...
متن کاملBone Marrow Transplantation in Thalassemia (Part 1)
During the last two decades conventional therapy has improved the prognosis of thalassemia. However, despite such improvement it still remains a progressive disease with treatment-related complications such as hepatitis, liver fibrosis, and cardiac disease. Bone marrow transplantation (BMT) can prevent or delay progression of the aforementioned complications. The importance of clinical research...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
گوارشجلد ۱۰، شماره ۲، صفحات ۷۴-۰
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023